Invention:
This invention is the development of pituitary adenylate cyclase activating peptide (PACAP) agonists for neuroprotection and antagonists for migraine.
Background:
PACAP is known as a neuronal survival factor, regulating the development, maintenance, function, and plasticity of neurons through activating PAC1, VPAC1, and VPAC2 receptors. Glycosylated PACAP analogues have been found to penetrate the blood-brain barrier (BBB) at a high rate. In addition, VPAC1/2 receptors are involved in vasodilation and may contribute to migraine attacks. It is possible to treat these migraine attacks by using PACAP antagonists.
Applications:
- A novel drug compound for the treatment of Parkinson’s disease and other neurodegenerative diseases
- May provide a novel technique to improve BBB permeability
Advantages:
- Improves BBB permeability
- Possible treatment of migraines
- Accessing the central nervous system through the BBB may provide better treatment options
Status: issued U.S. patent #10,858,410
